ABSTRACT: Background. Tobacco use is a risk factor for head and neck cancer, but effects on postoperative outcomes are unclear. Methods. Patients with head and neck cancer (n 5 89) were recruited before surgery. We assessed self-reported tobacco use status (never, former, or current) at study entry and recent tobacco exposure via urinary cotinine on surgery day. Outcomes included hospital length of stay (LOS) and complications. Results. Most participants reported current (32.6%) or former (52.8%) tobacco use; 43.2% were cotinine-positive on surgery day. Complications occurred in 41.6% and mean LOS was 4.0 and 8.8 days in patients who received low and high acuity procedures, respectively. Current and former smokers were over 6 times more likely to have complications than never smokers (p 5 .03). For high acuity procedures, LOS was increased in current (by 4.4 days) and former smokers (by 2.3 days; p 5 .02). Conclusion. Tobacco use status is associated with postoperative complications and may distinguish at-risk patients.
INTRODUCTION
Tobacco use is the primary risk factor for head and neck cancer. 1, 2 Roughly half of the patients reported smoking at the time of diagnosis and one-third continued to smoke during treatment. [3] [4] [5] Risk factors for continued smoking among patients with head and neck cancer include having relatives at home who smoke, greater nicotine dependence, less severe disease, less extensive treatment, and treatment completion. 3, 5, 6 The 2014 Surgeon General's Report highlights that smoking is related to both cancerspecific and all-cause mortality in patients with cancer. 7 In addition, continued tobacco use during and after cancer treatment increases the risk for cancer recurrence, second primary cancers, decreased quality of life, poor wound healing, skin and mucosal toxicities, and decreased survival time. 4, [8] [9] [10] [11] [12] [13] [14] [15] In contrast to the well-documented long-term effects of tobacco use, less is known about some of the short-term consequences, particularly during and immediately after cancer treatment. Some studies have demonstrated the detrimental effects of smoking on surgical wounds, [16] [17] [18] [19] but these have been mixed with regard to the relationship between tobacco use and postoperative outcomes, particularly within head and neck surgical patients. Tobacco use has been associated with infection, hemorrhage, fistula formation, as well as free flap necrosis in some studies. 20, 21 Other studies have reported no association with fistula formation or free flap survival. 10, 22, 23 Recently, Pattani et al 24 observed that tobacco users undergoing head and neck reconstruction had increased medical complications and increased postoperative hospital length of stay (LOS).
The existing research linking tobacco use to negative surgical outcomes has several methodological limitations. First, most studies define tobacco status using either selfreported or abstracted medical records data, both of which are subject to systematic measurement error. Studies find that self-reported tobacco use is often discordant with objective biomarkers of smoking, such as cotinine, the major metabolite of nicotine, particularly for recent quitters. 25, 26 Few studies investigating tobacco use and surgical outcomes of patients with head and neck cancer utilize an objective measure of tobacco use. In one study that did use both self-reported and cotinine measurement, elevated cotinine was significantly associated with flap complications, but self-reported tobacco use was not. 27 Second, most studies are based on retrospective designs. Third, the timing of the assessment of tobacco exposure has varied significantly across the studies. Using historical or self-reported data with inconsistent proximity to surgery date limits the ability to make conclusions concerning the relationships between smoking and surgical outcomes.
The present study addresses each of these limitations with a prospective examination of tobacco use and its relationship with head and neck cancer surgical outcomes, using two measures of tobacco use while controlling for other clinical factors. We examined the relationship between tobacco use, as assessed by both cotinine level on the day of surgery and self-reported smoking status at study entry, on postoperative hospital LOS and surgical complications in patients with head and neck cancer.
MATERIALS AND METHODS
This prospective study was conducted at two academic medical centers in North Carolina and South Carolina, with institutional review board approval from both centers. Patients were recruited from June 2011 to October 2012. Eligible participants were those 18 years and older with a stage I to IV squamous cell carcinoma of the upper aerodigestive tract who were scheduled to undergo a major surgical procedure. Procedures included any combination of tumor resection, neck dissection, and/or reconstruction. Minor surgical procedures, such as endoscopy or biopsy, were excluded.
Potential participants were identified through institution administrative and clinical databases and approached in outpatient clinics for recruitment. After written informed consent was obtained, participants completed a baseline questionnaire in person, by telephone, or mail and received a gift card. Questionnaires assessed demographic factors, including age, sex, race/ethnicity, and health insurance coverage (private vs public). Current or past tobacco use was assessed via validated questions from the Tobacco Use Supplement to the Current Population Survey 28 for: (1) history of smoking (smoked at least 100 cigarettes in life, yes or no); (2) current cigarette use (every day or some days vs not at all); (3) ever use of other tobacco products (smokeless, pipes, cigars, and others); and (4) current use of other tobacco products (every day or some days vs not at all). We categorized patient's self-reported smoking status at study entry as never users (smoked <100 lifetime cigarettes and no history of other tobacco products), former users (any history of cigarette or other tobacco use, but no current use), and current users (every day or occasional use of cigarettes and/or other tobacco products).
On the day of surgery, recent tobacco exposure was assessed by urinary cotinine using NicAlert, a semiquantitative colorimetric immunoassay developed by Nymox Pharmaceutical Corporation (Hasbrouck Heights, NJ). The NicAlert test strip provided a result numbered 0 to 6, and a value of 3 or greater from a urine sample indicates positive tobacco use in the previous 48 hours. 29 This cutoff was 95.0% sensitive and 94.8% specific for detecting tobacco use relative to urinary cotinine concentration by liquid chromatography tandem mass spectrometry in prior studies. 30 Two months after surgery, the medical record was reviewed and the following clinical factors were assessed: (1) postoperative hospital LOS in days calculated using surgical and discharge dates; (2) postoperative complications: categories included vascular, pulmonary, renal, acute blood loss anemia, ethanol withdrawal, wound, and other complications, such as urinary tract infection or delirium, unrelated to ethanol withdrawal; (3) acuity of the surgical procedure (high or low); surgical procedure acuity was derived from an adapted rating protocol derived from that originally described by authors at MD Anderson Cancer Center. 31, 32 High acuity procedures were considered as those that involved a surgical defect involving both skin and mucosal surfaces or a defect requiring pedicled or free flap reconstruction. Low acuity procedures included a surgical defect not including both skin and mucosal surfaces or neck dissections alone. Procedural acuity was reviewed for each case independently by 2 of the clinical study team members; discrepancies were discussed and resolved by consensus. (4) Type of procedure: resection, neck dissection, reconstruction, or combinations of these procedural categories. (5) American Society of Anesthesiologists (ASA) score 33 : determined by the anesthesiologist, an ASA of 1 or 2 includes healthy persons or those with mild systemic disease. Severe systemic disease or that which is a constant threat to life results in an ASA of 3 or 4; and (6) duration of surgery in hours.
In addition, we collected information from the medical records on (a) diagnosis type (new, recurrent/persistent disease); (b) tumor stage and location, as per American Joint Committee on Cancer (AJCC) TNM staging system 34 ; (c) previous treatment (surgery, chemotherapy, or radiation); and (d) medical comorbidities present before surgery, including cardiovascular (hypertension, coronary artery disease, congestive heart failure, and cerebrovascular and peripheral vascular disease), pulmonary (chronic obstructive pulmonary disease and asthma), diabetes mellitus, chronic renal insufficiency, and other conditions noted in the preoperative assessment.
Data analysis
We calculated descriptive statistics to describe the study population and their characteristics on the day of surgery. Because variance differed by acuity group and for ease of interpretation, we utilized general linear models stratified by procedure acuity to quantify the relationship between tobacco use and postoperative LOS. First, we fit unadjusted models for tobacco status at baseline and for cotinine status on the day of surgery. Next, to evaluate potential confounding, possible covariates (age, sex, non-Hispanic white race/ethnicity, insurance status, stage I/II/III vs IV, tumor site [oral cavity, oropharynx, hypopharynx/larynx, and other], recurrent or persistent disease, previous chemotherapy or radiation, number of procedures [resection, neck dissection, reconstruction], number of comorbidities, hours of surgery, ASA score 1-2 vs 3-4) were individually added to the univariate models, and factors significant at the p < .20 level were retained in the final multivariable model.
Frequencies of postoperative complications by acuity, cotinine status, and tobacco use at baseline were calculated. Differences in these frequencies were assessed using chi-square tests and Fisher's exact tests. Rate ratios, the ratio of the complication rates by tobacco use, were calculated overall and by acuity group. We fit an acuityadjusted logistic regression model to evaluate the impact of tobacco use on having any complication using the same procedure described above to introduce covariates. The final adjustment covariates were acuity, race/ethnicity, AJCC stage 1/2/3 vs 4, tumor site, number of procedures, hours of surgery, and ASA score 1/2 vs 3/4. All tests were 2-sided with an alpha level of 0.05 and performed in SAS v 9.3 (Cary, NC).
RESULTS

Patient characteristics
We approached 163 potential participants in the clinic and enrolled 129 (79% enrollment rate). Eighty-nine enrolled participants had complete data for analysis (with 1 participant missing cotinine). The majority of participants were men (74.2%) and either former smokers (52.8%) or current tobacco users (32.6%) at baseline ( Table 1 ). The mean time between last tobacco use and study enrollment in the former smoker group was 9 years (SD 5 9.6; range 5 0.03-36 years). More than half (53.9%) had advanced stage disease and 42.7% had recurrent or persistent disease. At the time of enrollment in the study, the vast majority of patients had some other medical comorbidity (87.6%), the most common being vascular disease (61.8%), pulmonary disease (19.1%), and diabetes (15.7%). Seventy-two patients (80.9%) had an ASA score of 3 or 4 at the time of surgery. Over half of the patients underwent a complex surgical procedure, including tumor resection, neck dissection, and reconstruction. High acuity procedures were more common (71.9% vs 28.1% low acuity).There was 86% agreement between self-reported tobacco use (at study entry) and urinary cotinine (on day of surgery). The agreement among never smokers was 100%.
Length of stay
The unadjusted mean LOS was 4.0 days for low acuity procedures and 8.8 days for high acuity procedures. On average, never smokers with low acuity procedures were discharged 1.5 days sooner (least square mean LOS 5 2.1 days) than those who were current smokers (least square mean LOS 5 3.9 days) or former smokers (least square mean LOS 5 3.6 days) in adjusted models, although this difference did not reach statistical significance. The adjusted means for those with positive and negative cotinine status were similar in unadjusted and adjusted models (Table 2) .
For the high acuity procedure group, we observed significant differences in LOS by self-reported tobacco use in unadjusted models, with means of 6.1 days for never smokers, 8.4 days for former smokers, and 10.5 days for current smokers (p for trend 5 .02); these differences were not statistically significant in adjusted models (p for trend 5 .13). Again, the adjusted mean LOS for those with positive and negative cotinine were similar (8.9 and 8.2 days, respectively).
Postoperative complications
Postoperative complications were observed in 16.0% of the patients in the low acuity group and 51.6% of the patients in the high acuity group (p 5 .002). A general pattern of greater complications in the high acuity patients was observed, with the greatest differences in acute blood loss anemia and wound complications (p 5 .02 and p 5 .03, respectively). Self-reported tobacco use at study entry was significantly associated with postoperative complications (Table  3) . Compared with never smokers, former and current smokers had complication rate ratios of 6.1 and 6.3, respectively. This was primarily driven by differences among the high acuity patients, among whom current smokers had rate ratios of almost 6, as compared to never smokers (58.3% vs 10%, respectively). The most prevalent complication types were pulmonary, acute blood loss anemia, and wound, but none of the rates of these individual complications were statistically significantly different by smoking history. Complication rates remained significantly higher in current or former smokers compared to never smokers after covariate adjustment (data not shown). In contrast, cotinine level was unrelated to postoperative complications (Table 4) .
DISCUSSION
It is well established that tobacco use is associated with poor cancer outcomes, including cancer recurrence, second primary cancers, decreased quality of life, poor wound healing, skin and mucosal toxicities, and decreased survival time. 4, [7] [8] [9] [10] [11] [12] [13] [14] [15] This study was carried out to assess the impact of tobacco use on acute treatment outcomes: LOS after surgical treatment and rates of postoperative complications in patients with head and neck cancer. We observed high rates of ever and current tobacco use in our study participants (85.4% of participants were former or current smokers and 43.2% had a positive cotinine test on the day of surgery).
Overall, we observed poorer postsurgical outcomes among both self-reported former and current smokers compared with never smokers. In particular, among patients with low acuity procedures, the adjusted mean LOS for former and current smokers were 71% and 86% longer, respectively, than never smokers; among patients with high acuity procedures, mean adjusted LOS in former and current smokers were 23% and 46% longer, respectively, than never smokers. The differences were more striking and statistically significant for postoperative complications, whereas former and current smokers had complication rate ratios of 6.1 and 6.3 compared to never smokers, respectively. Biochemically verified current smoking on the day of surgery was not associated with increased LOS or postoperative complication rates. The differences in complication rates and LOS when classifying smoking status by selfreport as opposed to cotinine levels on the day of surgery reaffirm the importance of smoking history (and not just current smoking) when assessing risk of postoperative complications in this patient population. This is only the second study to use cotinine to objectively measure tobacco use in this patient population in conjunction with postoperative outcomes assessment. In contrast to our findings, Marin et al 27 observed that elevated cotinine, but not self-reported smoking history, was correlated with postoperative wound complications. Differences in findings may be due to the narrower study population and outcomes in the Marin et al 27 study (wound complications after microvascular reconstruction only). We further explore issues surrounding concordance of self-report and urinary cotinine on the day of surgery in a second report from this study. Further research is necessary to assess the predictive value of cotinine for postoperative complications in a diverse sample of patients with head and neck cancer. Even though cotinine level on the day of surgery was not associated with postoperative complications, this does not minimize the importance of biological verification of smoking status in this or any other patient population. Given that many patients will misreport their smoking status, 35 and the long-standing association between smoking and outcomes of cancer treatment, 4, [7] [8] [9] [10] [11] [12] [13] [14] [15] the need to accurately identify, assess, and provide cessation treatment to all smokers is critical.
The trend of increased LOS among current smokers (unadjusted mean difference of >3 days more than never smokers) has both clinical and economic impact. Increased LOS has been linked to poor quality of life, increased risk of iatrogenic events, including nosocomial infection, and delay in beginning adjuvant therapy, for surgical oncology patients potentially worsening prognosis. [36] [37] [38] It has been estimated that similar complications to ones examined in this study may result in additional per patient costs of $11,000, whereas reduction in complications and LOS have the potential to save hospitals over $500,000 per year. 39, 40 Pulmonary complications, commonly seen in this patient population and in our study, can increase overall medical costs by 71%. 41 Hospital and physician reimbursement will become more dependent upon quality measures and patient outcomes under U.S. health care reform proposals. Current diagnosisrelated group reimbursement criteria are likely to become more stringent and payers even less likely to reimburse in the setting of extended LOS. In an environment of decreasing reimbursement and unfavorable hospital margins, the cost of treating smoking-related complications will continue to create financial pressure and instability in the health care system. This study is one of a few to examine the effects of tobacco not only according to patient history, but also with an objective measure to provide more detailed information about the type of tobacco exposure (ie, historical or immediate) and its impact on surgical outcomes. The prospective design and control of multiple clinical covariates in statistical analysis, including the number of procedures involved, duration of surgery, presence of comorbidities, and cancer stage, were strengths of the data analysis. Yet, several limitations are important to consider. (1) Given the relatively low incidence of specific types of complications, we were unable to determine if there were any differences in specific postoperative complications by tobacco status. Trends may be more apparent with more participants. (2) Because of limited sample size, we were also not able to assess differences within the former smoking group by duration of cessation. Those patients who stop using tobacco within a couple of weeks of surgery may have similar surgical outcomes as those who use tobacco on the day of surgery because medical benefits of quitting may manifest over time. [17] [18] [19] [20] In addition, we were not able to account for longitudinal changes in smoking status during the postsurgical period that may have impacted complications. Some participants had recently quit smoking resulting in a negative cotinine level, although the detrimental effects of tobacco use on pulmonary function may still be present. More pulmonary complications were seen in those with a positive cotinine level, although this difference was not statistically significant; a larger sample size would be needed to detect a statistically significant difference of this magnitude. Importantly, the duration of cessation needed to reduce postoperative risk is not known in this patient population and may vary by specific complication. (3) Another consideration not addressed in this study was human papillomavirus status of the tumor. Potential interactions between human papillomavirus status and smoking status should be examined in future studies.
CONCLUSIONS
In this study, self-reported tobacco use history was strongly associated with poorer surgical outcomes after head and neck surgery. This report adds to the growing evidence about the negative effects of tobacco on clinical outcomes in head and neck cancer and emphasizes the continued importance of history of tobacco use. Further research is needed to assess whether smoking cessation interventions improve surgical outcomes among patients with head and neck cancer and the duration of cessation needed to derive benefit. Knowledge of past or current tobacco use and the risk for complication in this population may provide an opportunity to implement risk reduction strategies.
